FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017676828> ?p ?o ?g. }

• W2017676828 endingPage "23092" @default.
• W2017676828 startingPage "23084" @default.
• W2017676828 abstract "Chronic inflammatory disorders, such as rheumatoid arthritis, are often accompanied by systemic bone loss, which is thought to occur through inflammatory cytokine-mediated stimulation of osteoclast resorption and inhibition of osteoblast function. However, the mechanisms involved in osteoblast inhibition remain poorly understood. Here we test the hypothesis that increased Smad ubiquitin regulatory factor 1 (Smurf1)-mediated degradation of the bone morphogenetic protein pathway signaling proteins mediates reduced bone formation in inflammatory disorders. Osteoblasts derived from bone marrow or long bone samples of adult tumor necrosis factor (TNF) transgenic (TNF-Tg) mice were used in this study. TNF decreased the steady-state levels of Smad1 and Runx2 protein similarly to those in long bones of TNF-Tg mice. In the presence of the proteasome inhibitor MG132, TNF increased accumulation of ubiquitinated Smad1 protein. TNF administration over calvarial bones caused decreases in Smad1 and Runx2 protein levels and mRNA expression of osteoblast marker genes in wild-type, but not in Smurf1-/- mice. Vertebral bone volume and strength of TNF-Tg/Smurf1-/- mice were examined by a combination of micro-CT, bone histomorphometry, and biomechanical testing and compared with those from TNF-Tg littermates. TNF-Tg mice had significantly decreased bone volume and biomechanical properties, which were partially rescued in TNF-Tg/Smurf1-/- mice. We conclude that in chronic inflammatory disorders where TNF is increased, TNF induces the expression of ubiquitin ligase Smurf1 and promotes ubiquitination and proteasomal degradation of Smad1 and Runx2, leading to systemic bone loss. Inhibition of ubiquitin-mediated Smad1 and Runx2 degradation in osteoblasts could help to treat inflammation-induced osteoporosis. Chronic inflammatory disorders, such as rheumatoid arthritis, are often accompanied by systemic bone loss, which is thought to occur through inflammatory cytokine-mediated stimulation of osteoclast resorption and inhibition of osteoblast function. However, the mechanisms involved in osteoblast inhibition remain poorly understood. Here we test the hypothesis that increased Smad ubiquitin regulatory factor 1 (Smurf1)-mediated degradation of the bone morphogenetic protein pathway signaling proteins mediates reduced bone formation in inflammatory disorders. Osteoblasts derived from bone marrow or long bone samples of adult tumor necrosis factor (TNF) transgenic (TNF-Tg) mice were used in this study. TNF decreased the steady-state levels of Smad1 and Runx2 protein similarly to those in long bones of TNF-Tg mice. In the presence of the proteasome inhibitor MG132, TNF increased accumulation of ubiquitinated Smad1 protein. TNF administration over calvarial bones caused decreases in Smad1 and Runx2 protein levels and mRNA expression of osteoblast marker genes in wild-type, but not in Smurf1-/- mice. Vertebral bone volume and strength of TNF-Tg/Smurf1-/- mice were examined by a combination of micro-CT, bone histomorphometry, and biomechanical testing and compared with those from TNF-Tg littermates. TNF-Tg mice had significantly decreased bone volume and biomechanical properties, which were partially rescued in TNF-Tg/Smurf1-/- mice. We conclude that in chronic inflammatory disorders where TNF is increased, TNF induces the expression of ubiquitin ligase Smurf1 and promotes ubiquitination and proteasomal degradation of Smad1 and Runx2, leading to systemic bone loss. Inhibition of ubiquitin-mediated Smad1 and Runx2 degradation in osteoblasts could help to treat inflammation-induced osteoporosis. Osteoporosis and fragility fractures are common and preventable complications of rheumatoid arthritis (RA). 2The abbreviations used are:RArheumatoid arthritisSmurf1Smad ubiquitin regulatory factor 1BMPbone morphogenetic proteinTgtransgenicTNFtumor necrosis factorWTwild typePBSphosphate-buffered salineCTcomputed tomographyMEKK2mitogen-activated protein kinase kinase 2JNKc-Jun NH2-terminal kinaseMAPKmitogen-activated protein kinaseALPalkaline phosphatase. For example, one study has reported that 53.3% of RA patients had osteoporosis and 19.3% had vertebral fractures, rates that are much higher than those of the general population (1Nakayama H. Clin. Calcium. 2007; 17: 1607-1612PubMed Google Scholar). These complications are thought to occur through inflammatory stimulation of osteoclast bone resorption and inhibition of osteoblast function (2Goldring S.R. Calcif. Tissue Int. 2003; 73: 97-100Crossref PubMed Scopus (109) Google Scholar) mediated by cytokines, such as TNF (3Nair S.P. Williams R.J. Henderson B. Rheumatology. 2000; 39: 821-834Crossref PubMed Scopus (46) Google Scholar, 4Srivastava S. Weitzmann M.N. Cenci S. Ross F.P. Adler S. Pacifici R. J. Clin. Investig. 1999; 104: 503-513Crossref PubMed Scopus (225) Google Scholar, 5Eigler A. Endres S. Z. Gastroenterol. 1997; 35: 899-901PubMed Google Scholar). TNF and other cytokines are overproduced by various cells in the inflamed joints of RA patients, which lead to severe local erosion of cartilage and bone, as well as periarticular osteopenia and systemic osteoporosis. rheumatoid arthritis Smad ubiquitin regulatory factor 1 bone morphogenetic protein transgenic tumor necrosis factor wild type phosphate-buffered saline computed tomography mitogen-activated protein kinase kinase 2 c-Jun NH2-terminal kinase mitogen-activated protein kinase alkaline phosphatase. TNF is a strong inhibitor of osteoblast functions in vitro, but the molecular mechanisms that mediate the inhibitory effects of TNF on osteoblasts have not been fully investigated. TNF inhibits the recruitment of osteoblast progenitors, reduces expression of genes produced by mature osteoblasts, and promotes osteoblast apoptosis through the NF-κB pathway (6Li Y.P. Stashenko P. J. Immunol. 1992; 148: 788-794PubMed Google Scholar, 7Taichman R.S. Hauschka P.V. Inflammation. 1992; 16: 587-601Crossref PubMed Scopus (90) Google Scholar, 8Kitajima I. Soejima Y. Takasaki I. Beppu H. Tokioka T. Maruyama I. Bone. 1996; 19: 263-270Crossref PubMed Scopus (116) Google Scholar, 9Jilka R.L. Weinstein R.S. Bellido T. Parfitt A.M. Manolagas S.C. J. Bone Miner. Res. 1998; 13: 793-802Crossref PubMed Scopus (472) Google Scholar, 10Gilbert L. He X. Farmer P. Boden S. Kozlowski M. Rubin J. Nanes M.S. Endocrinology. 2000; 141: 3956-3964Crossref PubMed Scopus (0) Google Scholar). It decreases the expression and DNA binding activity of runt-related transcription factor 2 (Runx2), which is partially through suppression of Runx2 gene transcription and destabilization of Runx2 mRNA through the TNF receptor 1 signaling pathway (11Gilbert L. He X. Farmer P. Rubin J. Drissi H. van Wijnen A.J. Lian J.B. Stein G.S. Nanes M.S. J. Biol. Chem. 2002; 277: 2695-2701Abstract Full Text Full Text PDF PubMed Scopus (377) Google Scholar, 12Abbas S. Zhang Y.H. Clohisy J.C. Abu-Amer Y. Cytokine. 2003; 22: 33-41Crossref PubMed Scopus (115) Google Scholar, 13Gilbert L.C. Rubin J. Nanes M.S. Am. J. Physiol. 2005; 288: E1011-E1018Crossref PubMed Scopus (102) Google Scholar). Recently, we demonstrated that TNF increases the expression of Smad ubiquitin regulatory factor-1 (Smurf1) in osteoblasts and promotes the proteasomal degradation of Runx2 protein in osteoblast cell lines (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar), suggesting that the proteasomal regulation of key transcription factors in osteoblasts may play an important role in inflammation-induced bone loss. Smurf1 was identified as an interacting protein with high homology to the homologous to E6-AP C terminus subclass of E3 ubiquitin ligases using Xenopus Smad1 as bait (15Zhu H. Kavsak P. Abdollah S. Wrana J.L. Thomsen G.H. Nature. 1999; 400: 687-693Crossref PubMed Scopus (693) Google Scholar). It negatively regulates osteoblast functions by promoting ubiquitination and proteasomal degradation of bone morphogenetic protein (BMP) signaling molecules, including Runx2 and Smads 1 and 5 in vitro (16Chen D. Zhao M. Mundy G.R. Growth Factors. 2004; 22: 233-241Crossref PubMed Scopus (1735) Google Scholar, 17Izzi L. Attisano L. Oncogene. 2004; 23: 2071-2078Crossref PubMed Scopus (217) Google Scholar, 18Datto M. Wang X.F. Cell. 2005; 121: 2-4Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar). Small peptides that block Smurf1 from binding to Smads increase osteoblast functions (19Sangadala S. Boden S.D. Viggeswarapu M. Liu Y. Titus L. J. Biol. Chem. 2006; 281: 17212-17219Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). We have used genetic approaches to demonstrate that both overexpression of Smurf1 in osteoblasts by type I collagen promoter or deletion of Smurf1 cause bone phenotypes. Smurf1 transgenic mice have decreased bone volume and reduced bone formation rates at 3–4-month of age (20Zhao M. Qiao M. Oyajobi B.O. Mundy G.R. Chen D. J. Biol. Chem. 2003; 278: 27939-27944Abstract Full Text Full Text PDF PubMed Scopus (239) Google Scholar). In contrast, Smurf1-/- mice have an age-dependent increase in bone mass. Thus, Smurf1 appears to play important roles in regulating bone mass in adult mice under normal physiologic conditions. However, the role of Smurf1 in pathologic bone loss has not been studied. Recently, we observed a significant reduction in bone volume in long bones of TNF transgenic (TNF-Tg) mice with established arthritis and a decrease in mineralized bone nodule formation from cells derived from bone marrow of these mice compared with wild-type (WT) littermates (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). Along with our previous finding that TNF increases Smurf1 expression in osteoblast cell lines (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar), we hypothesize that in TNF-Tg mice, Smurf1-mediated degradation of BMP signaling proteins is increased in osteoblasts, leading to reduced bone formation. Deletion of Smurf1 prevents bone loss in TNF-Tg mice. In the present studies, we demonstrated that Smurf1 protein expression is significantly increased in bones from TNF-Tg mice, which is associated with decreased Runx2 and Smad1 protein levels. The mice have reduced bone volumes and biomechanical parameters of bone strength. Smurf1 deletion prevents systemic bone loss and improves bone strength in TNF-Tg mice. Thus, our findings provide a novel molecular mechanism of TNF-induced inhibition in osteoblast function and BMP signaling, which involves post-transcriptional regulation of protein levels through Smurf1 E3 ligase-mediated proteasomal degradation. Animals—We used 4–8-month-old animals in this study because alteration of bone volume occurs in adult genetic-modified Smurf1 mice and TNF-Tg mice (20Zhao M. Qiao M. Oyajobi B.O. Mundy G.R. Chen D. J. Biol. Chem. 2003; 278: 27939-27944Abstract Full Text Full Text PDF PubMed Scopus (239) Google Scholar). TNF-Tg mice (3647 TNF-Tg line) were originally obtained from Dr. G. Kollias and characterized by us (21Li P. Schwarz E.M. O'Keefe R.J. Ma L. Looney R.J. Ritchlin C.T. Boyce B.F. Xing L. Arthritis Rheum. 2004; 50: 265-276Crossref PubMed Scopus (185) Google Scholar). TNF-Tg mice have elevated serum TNF levels when they reach 2 months of age or older (mean concentration is 100 pg/ml, range 48–120) (21Li P. Schwarz E.M. O'Keefe R.J. Ma L. Looney R.J. Ritchlin C.T. Boyce B.F. Xing L. Arthritis Rheum. 2004; 50: 265-276Crossref PubMed Scopus (185) Google Scholar), which is compatible to published (22Di Comite G. Marinosci A. Di Matteo P. Manfredi A. Rovere-Querini P. Baldissera E. Aiello P. Corti A. Sabbadini M.G. Ann. N. Y. Acad. Sci. 2006; 1069: 428-437Crossref PubMed Scopus (34) Google Scholar) serum TNF concentrations in RA patients (mean concentration was 71.2 pg/ml, range 10.7–556.5), making this model a close mimic of adult RA clinical presentations. They were crossed with C57/BL6 mice for 8 generations. Smurf1-/- mice are in a C57/BL6 background, as we described previously (23Yamashita M. Ying S.X. Zhang G.M. Li C. Cheng S.Y. Deng C.X. Zhang Y.E. Cell. 2005; 121: 101-113Abstract Full Text Full Text PDF PubMed Scopus (291) Google Scholar). TNF-Tg/Smurf1-/- mice were generated by inter-crossing TNF-Tg and Smurf1+/- mice to generate the TNF-Tg/Smurf1+/- F1 generation; then these F1 mice were crossed with Smurf1+/- mice to generate TNF-Tg/Smurf1-/- mice. The Institutional Animal Care and Use Committee approved all studies. Antibodies—Monoclonal antibodies specific for c-Myc and β-Actin were purchased from Sigma; anti-Runx2 monoclonal antibody was from MBL (Woburn, MA); anti-Smad1/5 and anti-Ubiquitin monoclonal antibody was from Santa Cruz (Santa Cruz, CA); anti-pSmad1/5 polyclonal antibody was from Cell Signaling (Danvers, MA); and anti-Smurf1 polyclonal antibody was obtained from Abgent (San Diego, CA). Cell Culture and Transfection Conditions—2T3 osteoblast precursors were cultured in α-minimal essential medium supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS). When cells reached 90% confluence, the cDNA expression plasmid, pCMV-Myc-tagged Smad1 (M-Smad1), and/or a pCMV-FLAG-tagged Smurf1 (F-Smurf1) were transiently transfected into the cells using Lipofectamine™ 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions. Total amounts of transfected plasmids in each group were equalized by the addition of an empty vector. After transfection, the cells were further cultured in the presence and absence of TNF + the proteasome inhibitor, MG132 (Calbiochem, La Jolla, CA), and subjected to Western blot analysis. Primary Bone Marrow Osteoblast Cultures—To generate bone marrow-derived osteoblasts from mice, bone marrow cells were flushed from femoral and tibial bones and cultured in α-medium plus 20% fetal bovine serum for 7 days to generate mesenchymal stromal cells. The cells were then cultured in osteoblast inducing medium (α-minimal essential medium containing 10% fetal bovine serum with 50 μg/ml ascorbic acid, 10 mm β-glycerophosphate) and treated with phosphate-buffered saline (PBS) or TNF (7.5 ng/ml) for various times. For human bone marrow osteoblast cultures, human mesenchymal stromal cells were isolated, as we described previously (24Ito H. Goater J.J. Tiyapatanaputi P. Rubery P.T. O'Keefe R.J. Schwarz E.M. Gene Ther. 2004; 11: 34-41Crossref PubMed Scopus (43) Google Scholar). Briefly, bone marrow aspirates were obtained from the iliac crests of patients during spinal surgery after informed consent under a protocol approved by the Institutional Review Board at the University of Rochester Medical Center. These were mixed with equal volumes of PBS. One volume of lymphocyte separation medium (Mediatech, Inc., Herndon, VA) was then slowly layered underneath the aspirate/PBS mixture to isolate mononuclear cells. The mononuclear cells were cultured in α-minimal essential medium plus 10% fetal bovine serum for 24 h and adherent cells were incubated for further expansion. Second to third passages of these human mesenchymal stromal cells were used in subsequent experiments. Cells were cultured in osteoblast inducing medium in the presence or absence of TNF, as described above. Real-time Quantitative Reverse Transcriptase-PCR—Total RNA was extracted from cell cultures or bone samples using TRIzol reagent (Invitrogen). Bone samples were cut into small pieces and homogenized in TRIzol reagent. Expression levels of Smurf1, Smurf2, alkaline phosphatase (ALP), osteocalcin, RANKL, osteoprotegrin, and β-actin mRNA were examined using quantitative real-time PCR amplification and sequence-specific primers, as described previously (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar, 25Mimura T. Amano S. Usui T. Kaji Y. Oshika T. Ishii Y. Exp. Eye Res. 2001; 72: 71-78Crossref PubMed Scopus (53) Google Scholar). Western Blot Analysis—Cells were lysed with mammalian protein extraction reagent (Pierce) containing a protease inhibitor mixture (Roche Applied Science). Long bone samples were cut into small pieces and homogenized in tissue protein extraction reagent (Pierce). Samples were resolved by 12% SDS-PAGE gel, transferred to a nitrocellulose membrane, and immunoblotted with individual antibodies. Membranes were then washed and incubated with a horseradish peroxidase-conjugated secondary antibody (Bio-Rad) and visualized by an enhanced chemiluminesence system (Amersham Biosciences) according to the manufacturer's instructions. Ubiquitination Assay—2T3 cells were transfected with M-Smad1 and treated with TNF for 72 h + MG132 for the last 4 h of TNF treatment. Cell lysates were incubated with anti-Myc antibody and protein G-agarose (Sigma) overnight at 4 °C. In some experiments, calvarial pre-osteoblasts were isolated from 3–5-day-old pups from Smurf1-/- and WT mice, as published previously (26Franzoso G. Carlson L. Xing L. Poljak L. Shores E.W. Brown K.D. Leonardi A. Tran T. Boyce B.F. Siebenlist U. Genes Dev. 1997; 11: 3482-3496Crossref PubMed Scopus (870) Google Scholar). Cells were treated with TNF for 72 h plus MG132 for the last 4 h. Total Smad1 protein was immunoprecipitated with anti-Smad1 antibody. The immunoprecipitates were washed with 50 mm Tris-HCl buffer (pH 8.0), containing 150 mm NaCl, 1% Nonidet P-40, 0.05% deoxycholate, and 0.1% SDS, resuspended in 2× reducing sample buffer, and subjected to Western blot analysis with an anti-ubiquitin antibody, as described previously (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar, 27Shen R. Chen M. Wang Y.J. Kaneki H. Xing L. O'Keefe R.J. Chen D. J. Biol. Chem. 2006; 281: 3569-3576Abstract Full Text Full Text PDF PubMed Scopus (129) Google Scholar). Microcomputed Tomography (Micro-CT)—The fourth lumbar vertebra (L4) was used for micro-CT and mechanical testing because our preliminary study demonstrated that L4 gave the smallest inter-sample variation in mechanical testing perhaps due to its large size and ease of dissection compared with L5–7. L4 vertebrae were scanned at high resolution (10.5 μm) on a VivaCT40 micro-CT scanner (Scanco Medical, Basserdorf, Switzerland) using an integration time of 300 ms, energy of 55 kVp, and intensity of 145 μA. A volume of interest for quantitative analysis of trabecular bone was defined, extending from the proximal to the distal end of the vertebrae. The three-dimensional images were generated using a constant threshold of 275 for all samples. For each sample, bone volume fraction, trabecular number, trabecular thickness, trabecular separation, and connectivity density were measured. Mechanical Testing—The L4 vertebra was used and mechanical testing was performed according to a published method with a minor modification (28Silva M.J. Brodt M.D. Uthgenannt B.A. Bone. 2004; 35: 425-431Crossref PubMed Scopus (31) Google Scholar). In brief, the L4 was dissected of soft tissue and the vertebral body was isolated from the posterior elements by cutting the pedicles with a 10-mm diameter diamond saw. The end plates of the vertebral body were cemented onto small plastic plates using bone cement (DePuy Orthopaedics, Inc., Warsaw, IN), to ensure axial alignment of the bodies and to distribute the load evenly on the surface of the cemented end plates. The specimens were then hydrated in PBS for 2 h at room temperature. The vertebral bodies were tested in compression at a rate of 1 mm/min until failure using an Instron DynaMight 8841 servo-hydraulic materials testing machine (Instron, Norwood, MA). Maximum compressive load at failure (N), maximum deformation at maximum force (mm), stiffness (N/mm), and energy to failure (area under the curve) (N.mm) were measured from the recorded load-deformation curves using MATLAB software (The Mathworks, Natick, MA). Histology—Paraffin sections were stained with H&E or for TRAP activity. Histomorphometric analyses were performed using an OsteoMeasure program (Osteometrics, Atlanta, GA) (21Li P. Schwarz E.M. O'Keefe R.J. Ma L. Looney R.J. Ritchlin C.T. Boyce B.F. Xing L. Arthritis Rheum. 2004; 50: 265-276Crossref PubMed Scopus (185) Google Scholar). Peri-articular inflammation (mm2) and eroded articular surface (%) were measured around knee joints and the number of osteoclast per millimeter bone surface was countered in the proximal tibiae region. Statistics Analysis—Data are presented as mean ± S.D., and all experiments were performed at least twice with similar results. Statistical analyses were performed with StatView statistical software (SAS, Cary, NC). Differences between the two groups were compared using un-paired Student's t test and more than two groups were compared using one-way analysis of variance, followed by a Bonferroni/Dunnet test. p values less than 0.05 were considered to be statistically significant. Chronic TNF Treatment of Mouse and Human Bone Marrow-derived Osteoblasts Increases Smurf1 and Reduces Basal Smad1 and Runx2 Protein Expression—Systemic osteoporosis occurs often in patients suffering from chronic inflammatory disorders and in TNF-Tg mice that have been chronically exposed to elevated blood TNF levels and have developed RA-like arthritis (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). Previously, we found that treatment of 2T3 pre-osteoblasts with TNF for 3 days increases Smurf1 expression and proteasomal degradation of Runx2 (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar), leading to a hypothesis that elevated Smurf1-mediated BMP-signaling protein degradation may contribute to reduced osteoblast function in TNF-Tg mice. To test this hypothesis, we first attempted to establish a culture protocol that mimics the in vivo situation of TNF-Tg mice. Bone marrow mesenchymal stromal cells from 4–8-month-old WT mice were cultured in the osteoblast inducing medium and treated with TNF for 20 days. The expression levels of osteoblast marker genes were examined. TNF decreased the expression of ALP and osteocalcin starting from day 8, which became more significant thereafter, whereas ALP and osteocalcin expression increased markedly in PBS-treated cells (Fig. 1). In contrast, TNF-induced decreased ALP expression occurs usually much earlier in calvaria-derived or 2T3 pre-osteoblast cells (at about 24 h after TNF treatment, data not shown). These findings suggest that primary bone marrow-derived osteoblasts may respond to TNF differently and we decided to use 14-day TNF treatment as a protocol in our subsequent study. Under this culture condition, TNF decreased phosphorylated and total Smad1/5 as well as Runx2 protein levels and increased Smurf1 expression (Fig. 2, A and B). To determine whether this inhibitory effect of TNF on Smad1/5 and Runx2 protein expression also happened in vivo, we examined long bones of 4–5-month-old TNF-Tg mice, which had developed severe inflammatory arthritis and systemic bone loss. We found that Smurf1 protein expression was increased and phospho-Smad1/5, total Smad1/5, and Runx2 protein levels as well as ALP mRNA expression levels were decreased in bones from TNF-Tg mice compared with WT mice (Fig. 2, C and D). To determine whether these inhibitory effects of TNF also occur in human osteoblasts, we treated osteoblasts derived from human bone marrow stromal cells with TNF. TNF increased Smurf1, decreased ALP, and had no effect on Smurf2 mRNA expression in human cells (Fig. 2E). The expression of phospho-Smad1/5, total Smad1/5, and Runx2 protein levels was significantly decreased in TNF-treated cells (Fig. 2F). TNF Promotes Proteasomal Degradation of Smad1 through Smurf1-mediated Ubiquitination—We have demonstrated previously that Smurf1 mediates TNF-induced reduction in Runx2 protein levels in the 2T3 preosteoblast cell line (14Kaneki H. Guo R. Chen D. Yao Z. Schwarz E.M. Zhang Y.E. Boyce B.F. Xing L. J. Biol. Chem. 2006; 281: 4326-4333Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). To determine whether TNF also affects Smad1 protein degradation through Smurf1, we transiently co-transfected 2T3 cells with M-Smad1 and F-Smurf1 expression vectors and treated them with TNF. TNF decreased exogenous Smad1 protein expression, assessed using an anti-c-Myc antibody, to a degree similar to that seen in cells overexpressing Smurf1 (Fig. 3A). To test if this was mediated by promoting ubiquitination and proteasomal degradation of Smad1, we treated cells with TNF + the proteasome inhibitor, MG132. Smad1 protein was immunoprecipitated with anti-c-Myc antibody and expression was assessed by Western blot using an anti-Ubiquitin antibody. In the presence of MG132, TNF increased the accumulation of ubiquitinated-Smad1 protein (Fig. 3B), indicating that TNF induces Smad1 ubiquitination and results in its rapid breakdown through proteasomal degradation. TNF-decreased Smad1 Protein Levels Are Attenuated in Smurf1-/- Mice—If Smurf1 mediates TNF-induced inhibition of osteoblast function, the effect should be attenuated or abolished in the absence of Smurf1. To examine this possibility, we generated TNF-Tg/Smurf1-/- mice and examined their bones when they were 7–8 months old. ALP and osteocalcin mRNA and Smads and Runx2 protein levels were examined. ALP and osteocalcin mRNA expression and Smad1/5 and Runx2 protein levels were decreased in TNF-Tg mice and these were restored to the WT levels in TNF-Tg/Smurf1-/- mice (Fig. 4, A and B). To confirm that TNF-induced decrease Smad1 protein levels is through Smurf1-mediated Smad1 ubiquitination in vivo, we treated calvarial pre-osteoblasts from Smurf1-/- and WT mice with TNF and subjected them to a ubiquitination assay. As shown in the 2T3 preosteoblast cell line, TNF increased the ubiquitination of endogenous Smad1 protein, which was prevented in cells from Smurf1-/- mice (Fig. 4C). Smurf1 Deletion Attenuates Reduction in Bone Volume and Strength in TNF-Tg Mice—To determine whether Smurf1 deletion prevents the systemic bone loss in TNF-Tg mice, we analyzed vertebral bones of TNF-Tg/Smurf1-/- mice and compared them with WT, Smurf1-/-, and TNF-Tg mice from the same litters using micro-CT, histology, and mechanical testing. We used vertebral bones in these studies because persistent severe inflammation in the knee and ankle joints of TNF-Tg mice cause deformation and destruction of joints and, in some cases, damage to the epiphyses of femora and tibiae due to massive bone remodeling. This prohibited us from reliably examining the role of Smurf1 deletion in bone loss of the long bones of these mice. Micro-CT analyses of cancellous regions of the vertebrae (Fig. 5, A and B) show that the bone volume of Smurf1-/- mice was significantly increased as previously reported in long bones of these mice (23Yamashita M. Ying S.X. Zhang G.M. Li C. Cheng S.Y. Deng C.X. Zhang Y.E. Cell. 2005; 121: 101-113Abstract Full Text Full Text PDF PubMed Scopus (291) Google Scholar). TNF-Tg mice had a statistically significant decrease in bone volume, particularly in the middle portions of the vertebral bodies (see box in the Fig. 5A). Bone volume was restored to WT levels in TNF-Tg/Smurf1-/- mice (Fig. 5B). In contrast, micro-CT analysis of cortical regions in the same vertebrae found that both TNF-Tg and TNF-Tg/Smurf1-/- mice had significantly reduced cortical bone thickness compared with WT or Smurf1-/- mice (cortical thickness (mm): 0.236 ± 0.020 in WT, 0.211 ± 0.026 in Smurf1-/-, *0.190 + 0.016 in TNF-Tg, and *0.186 ± 0.012 in TNF-Tg/Smurf1-/- mice; *, p < 0.05 versus WT mice). The micro-CT findings were confirmed histologically (supplemental Fig. S2). Osteoporosis is typically associated with reduced bone strength. To examine if TNF-Tg mice have reduced bone quality and if this can be rescued by Smurf1 deletion, we examined the compressive biomechanical properties of mouse vertebral bones using a modified Instron material testing system (28Silva M.J. Brodt M.D. Uthgenannt B.A. Bone. 2004; 35: 425-431Crossref PubMed Scopus (31) Google Scholar). The biomechanical properties measured include maximum deformation, maximum compressive load at failure, energy to failure, and stiffness. Compared with WT littermates, TNF-Tg mice have significantly reduced biomechanical properties except stiffness (Fig. 6, A and B). TNF-Tg/Smurf1-/- mice have improved mechanical strength in certain degrees. The maximum compressive load in TNF-Tg/Smurf1-/- mice was higher than in TNF-Tg mice and restored to the WT levels. Their energy to failure was improved compared with TNF-Tg mice but still lower than in WT mice (Fig. 6B). The maximum deformation was unchanged between TNF-Tg/Smurf1-/- and TNF-Tg mice, both of which were significantly lower than WT mice (Fig. 6B). In addition, there were no differences in Smurf1-/- and WT mice vertebral biomechanical properties except stiffness. TNF is known to stimulate osteoclast formation and bone erosion in joints of RA patients and animals (29Goldring S.R. Rheumatology (Oxford). 2003; 42: ii11-ii16PubMed Google Scholar). To determine whether partially restored bone mass in TNF-Tg/Smurf1-/- mice is due to potent influence of Smurf1 on osteoclast function, we examined osteoclast number and local bone erosion in knee jo" @default.
• W2017676828 created "2016-06-24" @default.
• W2017676828 creator A5014120233 @default.
• W2017676828 creator A5015732221 @default.
• W2017676828 creator A5020642963 @default.
• W2017676828 creator A5031574868 @default.
• W2017676828 creator A5036125160 @default.
• W2017676828 creator A5052441498 @default.
• W2017676828 creator A5062251241 @default.
• W2017676828 creator A5066795908 @default.
• W2017676828 creator A5067493822 @default.
• W2017676828 creator A5072046074 @default.
• W2017676828 creator A5074891524 @default.
• W2017676828 creator A5078788379 @default.
• W2017676828 creator A5083101816 @default.
• W2017676828 date "2008-08-01" @default.
• W2017676828 modified "2023-10-15" @default.
• W2017676828 title "Ubiquitin Ligase Smurf1 Mediates Tumor Necrosis Factor-induced Systemic Bone Loss by Promoting Proteasomal Degradation of Bone Morphogenetic Signaling Proteins" @default.
• W2017676828 cites W1519258930 @default.
• W2017676828 cites W1922207530 @default.
• W2017676828 cites W1965044262 @default.
• W2017676828 cites W1971166655 @default.
• W2017676828 cites W1973598383 @default.
• W2017676828 cites W1974493433 @default.
• W2017676828 cites W1989412856 @default.
• W2017676828 cites W1989715180 @default.
• W2017676828 cites W1994266452 @default.
• W2017676828 cites W1997359253 @default.
• W2017676828 cites W2006062243 @default.
• W2017676828 cites W2006385099 @default.
• W2017676828 cites W2012448313 @default.
• W2017676828 cites W2020457805 @default.
• W2017676828 cites W2022140268 @default.
• W2017676828 cites W2022598782 @default.
• W2017676828 cites W2041918011 @default.
• W2017676828 cites W2042128990 @default.
• W2017676828 cites W2049293744 @default.
• W2017676828 cites W2057521146 @default.
• W2017676828 cites W2057767897 @default.
• W2017676828 cites W2058733924 @default.
• W2017676828 cites W2059194853 @default.
• W2017676828 cites W2066612343 @default.
• W2017676828 cites W2071035473 @default.
• W2017676828 cites W2075292460 @default.
• W2017676828 cites W2085016903 @default.
• W2017676828 cites W2085627522 @default.
• W2017676828 cites W2095995789 @default.
• W2017676828 cites W2129638584 @default.
• W2017676828 cites W2135809272 @default.
• W2017676828 cites W2146696914 @default.
• W2017676828 cites W2148676064 @default.
• W2017676828 cites W2157009361 @default.
• W2017676828 cites W2159660733 @default.
• W2017676828 cites W2167033587 @default.
• W2017676828 cites W2170551980 @default.
• W2017676828 cites W4244095134 @default.
• W2017676828 doi "https://doi.org/10.1074/jbc.m709848200" @default.
• W2017676828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2517001" @default.
• W2017676828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18567580" @default.
• W2017676828 hasPublicationYear "2008" @default.
• W2017676828 type Work @default.
• W2017676828 sameAs 2017676828 @default.
• W2017676828 citedByCount "125" @default.
• W2017676828 countsByYear W20176768282012 @default.
• W2017676828 countsByYear W20176768282013 @default.
• W2017676828 countsByYear W20176768282014 @default.
• W2017676828 countsByYear W20176768282015 @default.
• W2017676828 countsByYear W20176768282016 @default.
• W2017676828 countsByYear W20176768282017 @default.
• W2017676828 countsByYear W20176768282018 @default.
• W2017676828 countsByYear W20176768282019 @default.
• W2017676828 countsByYear W20176768282020 @default.
• W2017676828 countsByYear W20176768282021 @default.
• W2017676828 countsByYear W20176768282022 @default.
• W2017676828 countsByYear W20176768282023 @default.
• W2017676828 crossrefType "journal-article" @default.
• W2017676828 hasAuthorship W2017676828A5014120233 @default.
• W2017676828 hasAuthorship W2017676828A5015732221 @default.
• W2017676828 hasAuthorship W2017676828A5020642963 @default.
• W2017676828 hasAuthorship W2017676828A5031574868 @default.
• W2017676828 hasAuthorship W2017676828A5036125160 @default.
• W2017676828 hasAuthorship W2017676828A5052441498 @default.
• W2017676828 hasAuthorship W2017676828A5062251241 @default.
• W2017676828 hasAuthorship W2017676828A5066795908 @default.
• W2017676828 hasAuthorship W2017676828A5067493822 @default.
• W2017676828 hasAuthorship W2017676828A5072046074 @default.
• W2017676828 hasAuthorship W2017676828A5074891524 @default.
• W2017676828 hasAuthorship W2017676828A5078788379 @default.
• W2017676828 hasAuthorship W2017676828A5083101816 @default.
• W2017676828 hasBestOaLocation W20176768281 @default.
• W2017676828 hasConcept C104317684 @default.
• W2017676828 hasConcept C134018914 @default.
• W2017676828 hasConcept C134459356 @default.
• W2017676828 hasConcept C17991360 @default.
• W2017676828 hasConcept C185592680 @default.
• W2017676828 hasConcept C202751555 @default.
• W2017676828 hasConcept C25602115 @default.
• W2017676828 hasConcept C30352789 @default.

• next